AGL 40.00 No Change ▼ 0.00 (0%)
AIRLINK 127.20 Increased By ▲ 0.16 (0.13%)
BOP 6.63 Decreased By ▼ -0.04 (-0.6%)
CNERGY 4.54 Increased By ▲ 0.03 (0.67%)
DCL 8.56 Increased By ▲ 0.01 (0.12%)
DFML 41.72 Increased By ▲ 0.28 (0.68%)
DGKC 87.40 Increased By ▲ 0.55 (0.63%)
FCCL 32.51 Increased By ▲ 0.23 (0.71%)
FFBL 64.87 Increased By ▲ 0.07 (0.11%)
FFL 10.23 Decreased By ▼ -0.02 (-0.2%)
HUBC 109.56 Decreased By ▼ -0.01 (-0.01%)
HUMNL 14.74 Increased By ▲ 0.06 (0.41%)
KEL 5.11 Increased By ▲ 0.06 (1.19%)
KOSM 7.56 Increased By ▲ 0.10 (1.34%)
MLCF 41.55 Increased By ▲ 0.17 (0.41%)
NBP 59.60 Decreased By ▼ -0.81 (-1.34%)
OGDC 192.74 Increased By ▲ 2.64 (1.39%)
PAEL 28.15 Increased By ▲ 0.32 (1.15%)
PIBTL 7.83 No Change ▼ 0.00 (0%)
PPL 151.25 Increased By ▲ 1.19 (0.79%)
PRL 27.10 Increased By ▲ 0.22 (0.82%)
PTC 15.99 Decreased By ▼ -0.08 (-0.5%)
SEARL 86.02 Increased By ▲ 0.02 (0.02%)
TELE 7.78 Increased By ▲ 0.07 (0.91%)
TOMCL 35.53 Increased By ▲ 0.12 (0.34%)
TPLP 8.17 Increased By ▲ 0.05 (0.62%)
TREET 16.46 Increased By ▲ 0.05 (0.3%)
TRG 53.25 Decreased By ▼ -0.04 (-0.08%)
UNITY 26.30 Increased By ▲ 0.14 (0.54%)
WTL 1.28 Increased By ▲ 0.02 (1.59%)
BR100 9,989 Increased By 105.1 (1.06%)
BR30 31,165 Increased By 565.3 (1.85%)
KSE100 94,195 Increased By 839.9 (0.9%)
KSE30 29,187 Increased By 255.6 (0.88%)

Bangladesh's leading drug maker Beximco Pharmaceuticals Limited (BPL) said on Saturday it has raised 6.5 million pounds through the issue of 8,175,750 further global depository receipts (GDRs) on the London Stock Exchange, each representing one ordinary share of 10 taka each at an issue price of 80 pence per GDR.
The newly issued GDRs were admitted for trading on June 1 on the Alternative Investment Market (AIM) of the London Stock Exchange, a BPL statement said.
"We have been delighted by the interest in Beximco from international investors since the company's IPO in London last year and we are grateful to them for their continuing support in this fundraising as we develop the infrastructure of our business and invest in its growth," said Nazmul Hassan, Chief Executive Officer of Beximco Pharmaceuticals said in the statement.

Copyright Reuters, 2006

Comments

Comments are closed.